Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00044083 |
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Tolcapone |
Phase II |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Crossover Assignment, Efficacy Study |
Official Title: | Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype |
Estimated Enrollment: | 210 |
Study Start Date: | August 2002 |
Psychopharmacological modulation of the catecholaminergic system can enhance some aspects of cognitive function. For example, COMT inhibitors can slightly improve working memory/executive function. Differences in the response between individuals might be related to a number of factors, including variations in the genes. The recent finding that a polymorphism in the catechol-o-methyl-transferase (COMT) gene, which produces a 4 fold change in enzyme activity, accounts for 4 percent of the variance in performance of working memory tasks in humans suggest that COMT genotype may predict response to COMT inhibitors. In the present proof of concept investigation our goal is to examine, in normal controls and patients with schizophrenia, the effect of a centrally acting (tolcapone) and of a peripherally acting (entacapone) COMT inhibitor on cognitive function. We predict that both normal controls and patients with schizophrenia with the val/val genotype will have a significant, though transient, improvement in working memory in subjects treated with tolcapone but not in those treated with entacapone. Furthermore, in conjunction with other NIMH imaging protocols, we would like to examine the neurophysiological correlates related to working memory. We predict, in tolcapone treated subjects, improved measures in prefrontal 'efficiency' in subjects and patients specifically with the val/val genotype. The present protocol will provide new insights on the importance of this genetic polymorphism in the regulation of aminergic-controlled cognitive function in normal individuals. Furthermore, this protocol will test whether COMT inhibitors offer a new treatment-based on genotype - for cognitive impairment in schizophrenia. No IND is required for the present study.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Responsible Party: | National Institutes of Health ( Jose A. Apud, M.D./National Institute of Mental Health ) |
Study ID Numbers: | 020239, 02-M-0239 |
Study First Received: | August 16, 2002 |
Last Updated: | October 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00044083 |
Health Authority: | United States: Federal Government |
Catecholamines Dopamine Clinical Trial fMRI PFC Vitamin B2 Riboflavin Tolcapone |
Placebo Normal Volunteers Schizophrenia Healthy Volunteers HV Vitamin B2 Riboflavin |
Schizophrenia Dopamine Riboflavin Mental Disorders Tolcapone |
Psychotic Disorders Healthy Schizophrenia and Disorders with Psychotic Features Entacapone |
Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Antiparkinson Agents |
Enzyme Inhibitors Central Nervous System Agents Pharmacologic Actions |